Bromopride

From Self-sufficiency
Revision as of 18:28, 28 April 2010 by Albmont (Talk) (pt:)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Bromopride
File:Bromopride.svg
Systematic (IUPAC) name
4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
Clinical data
Routes of
administration
Oral, IM, IV
Legal status
Legal status
Pharmacokinetic data
Bioavailability 50 to 75% (oral)
78% (intramuscular)
Protein binding 40%
Metabolism Hepatic
Biological half-life 4 to 5 hours
Excretion Renal, 10 to 14% unchanged
Identifiers
CAS Number 4093-35-0
ATC code A03FA04 (WHO)
PubChem CID 2446
ChemSpider 2352
Chemical data
Formula C14H22BrN3O2
Molar mass 344.248 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Bromopride (INN) is a dopamine antagonist with prokinetic properties widely used as an antiemetic, closely related to metoclopramide. It is not available in the United States.

Bromopride appears to be safe and effective for use in pregnancy.[1]

Indications

Bromopride is indicated in the treatment of nausea and vomiting, including postoperative nausea and vomiting (PONV); gastroesophageal reflux disease (GERD/GORD); and as preparation for endoscopy and radiographic studies of the gastrointestinal tract. The manufacturer also claims it is valuable in, among other indications, hiccups and gastrointestinal adverse effects of radiation therapy.

Adverse effects

Bromopride is generally well tolerated; the most common adverse effects of its use are somnolence and fatigue. Bromopride may rarely cause extrapyramidal symptoms and, as with metoclopramide, may increase prolactin levels.[2]

Chemistry

Bromopride is a substituted benzamide, closely related to metoclopramide.[3] It is identical to metoclopramide except for the presence of a bromine atom where metoclopramide has a chlorine substituent.

Availability

Bromopride is not available in the United States or the United Kingdom. It is marketed in Brazil by Sanofi-Synthélabo under the trade name Digesan and as a generic drug.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
pt:Bromoprida ru:Бромоприд
  1. Araújo JR (1981). "Evaluation of bromopride in nausea and vomiting of pregnancy". J Bras Ginecol (in Portuguese). 91 (4): 283–5. 
  2. "Bula do Profissional de Saúde: Bromoprida". Bulário Eletrônico da Anvisa (in Portuguese). Brazilian National Health Surveillance Agency. April 11, 2006. Retrieved 2007-07-23. 
  3. Brodie RR, Chasseaud LF, Darragh A, Lambe RF, Rooney L, Taylor T (1986). "Pharmacokinetics and bioavailability of the anti-emetic agent bromopride". Biopharm Drug Dispos. 7 (3): 215–22. doi:10.1002/bdd.2510070302. PMID 3730521.